CLINICAL TRIALS PROFILE FOR IVABRADINE HYDROCHLORIDE

All Clinical Trials for IVABRADINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00143507 ↗	The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction	Completed	Institut de Recherches Internationales Servier	Phase 3	2004-12-01	The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function.
NCT00202566 ↗	Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris	Completed	Institut de Recherches Internationales Servier	Phase 3	2005-06-01	To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris
NCT00202579 ↗	Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure	Completed	Institut de Recherches Internationales Servier	Phase 2	2004-09-01	To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure
NCT00757055 ↗	If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure	Withdrawn	St Vincent's University Hospital, Ireland	Phase 2	2012-12-01	The purpose of this study is to investigate whether the medicine ivabradine, a novel drug which slows the heart rate has a favourable effect on patients with diastolic heart failure. Ivabradine is a specific heart rate-lowering agent. It has a licence for treating patients with angina who are intolerant of agents such as beta blockers or whose angina is not adequately controlled. It has been shown to prolong exercise tolerance in these patients and to reduce the frequency of chest pain. Its mechanism of action is felt to be purely due to reducing heart rate, by as much as 10 beats per minute at rest, as well as by reducing the heart rate response to exercise. Patients with diastolic heart failure often complain of breathlessness on exertion which relates to the stiffness or lack of compliance of their heart i.e. the heart fails to relax rapidly enough to allow it to fill with blood between each heart beat. This may result in high pressure in the heart chamber which backs up in to the lungs and may be experienced as breathlessness. There is little evidence that any specific therapy benefits patients with this type of heart failure besides treating coexisting problems such as high blood pressure or angina. By slowing the heart rate down with ivabradine, the heart would have a longer time to fill during exercise which would make it more effective. This slowing of the heart rate may therefore relieve the breathlessness experienced on activity such as walking to the shops or up a flight of stairs etc.
NCT00815100 ↗	Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome	Completed	Hospital Universitario de Canarias	Phase 4	2009-04-01	The purpose of this study is to investigate whether a pure heart rate-lowering agent (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes
NCT00825123 ↗	Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals	Terminated	Baker Heart and Diabetes Institute	Phase 4	2008-10-01	The purpose of this project is to determine the effects of slowing heart rate upon both central and peripheral blood pressures using Ivabradine. The effects of Ivabradine will be compared to Metoprolol and placebo. Participants will attend the hospital for 3 visits where they will be randomised to receive either Ivabradine, Metoprolol and placebo on each visit. Non-invasive measures of blood pressure will be recorded before and after consuming the study drug.

Clinical Trial Conditions for IVABRADINE HYDROCHLORIDE

Condition Name

Condition Name for IVABRADINE HYDROCHLORIDE
Intervention	Trials
Heart Failure	14
Coronary Artery Disease	6
Atrial Fibrillation	5
Cardiogenic Shock	3

Condition MeSH

Condition MeSH for IVABRADINE HYDROCHLORIDE
Intervention	Trials
Heart Failure	32
Myocardial Ischemia	14
Coronary Artery Disease	12
Coronary Disease	9

Clinical Trial Locations for IVABRADINE HYDROCHLORIDE

Trials by Country

Trials by Country for IVABRADINE HYDROCHLORIDE
Location	Trials
United States	25
China	13
Italy	11
Egypt	8
United Kingdom	6

Trials by US State

Trials by US State for IVABRADINE HYDROCHLORIDE
Location	Trials
Michigan	3
Ohio	2
North Carolina	2
New York	2
Illinois	2

Clinical Trial Progress for IVABRADINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for IVABRADINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	3
PHASE2	2
Phase 4	35

Clinical Trial Status

Clinical Trial Status for IVABRADINE HYDROCHLORIDE
Clinical Trial Phase	Trials
COMPLETED	30
Unknown status	21
Recruiting	20

Clinical Trial Sponsors for IVABRADINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for IVABRADINE HYDROCHLORIDE
Sponsor	Trials
Amgen	6
Institut de Recherches Internationales Servier	6
Servier	3

Sponsor Type

Sponsor Type for IVABRADINE HYDROCHLORIDE
Sponsor	Trials
Other	118
Industry	11
OTHER_GOV	1

Ivabradine Hydrochloride Clinical Trials Update, Market Analysis and Revenue Projection (2026–2036)

Last updated: July 26, 2026

Ivabradine hydrochloride remains a cardiology niche asset built on heart failure (HFrEF) and chronic coronary syndrome use-cases, with market trajectory shaped by label geography, guideline adoption, and generic entry risk from small-molecule patent estates. No complete, source-backed clinical trials pipeline dataset and market sizing basis were provided, so a complete and accurate trials update and projection cannot be produced without fabricating inputs.

Clinical trials update for ivabradine hydrochloride: what studies are ongoing and results by phase?

Which trials are enrolling ivabradine hydrochloride in HFrEF or chronic coronary syndrome? A clinical-trials update requires a verified list of active/ongoing studies (identifier, sponsor, phase, enrollment status, primary endpoints, and last update date). Without a source dataset of registered trials, a factual phase-by-phase update would require guessing.

What phase 3 or phase 4 ivabradine hydrochloride readouts are expected in 2026–2030? A credible forward-looking timeline requires verified study start/completion dates or FDA/EMA communications. Without those inputs, any forecast would be speculative.

Do new combination regimens (ivabradine + beta blockers, ARNI, SGLT2 inhibitors) have outcome data? Combination evidence depends on specific trial programs and published endpoints. Without sourced trial publications or registry entries, this cannot be stated accurately.

Market analysis for ivabradine hydrochloride: how big is demand and who buys it?

How does ivabradine hydrochloride market split across heart failure and angina indications? Indication-level split requires market research or dispensing/claims analytics. No dataset is available here, so segment attribution would be unreliable.

What is the competitive landscape: originator vs generics and regional players? Competitive analysis requires a roster of marketed products by country, listing status (e.g., SmPC country authorizations), and major generic entrants. Without that, any company ranking would risk inaccuracy.

What are the key pricing and reimbursement drivers by geography? Pricing and coverage depend on HTA decisions and payer formularies. Without sourced payer outcomes and country-level pricing, projections would be ungrounded.

When does ivabradine hydrochloride lose exclusivity and what generic entry risks exist?

Orange Book status for ivabradine hydrochloride: what patents are listed and when do they expire? A patent-expiration and Orange Book status view requires the specific NDA/ANDA basis and Orange Book patent list. No Orange Book record is provided.

What patents protect ivabradine hydrochloride formulations and methods of use? Formulation and method-of-use protection requires the exact patent families tied to approved dosages, plus any subsequent patents. Without a sourced patent estate, protection mapping cannot be completed.

What Paragraph IV (ANDA) challenges are filed for ivabradine hydrochloride? Paragraph IV identification requires FDA case listings and complaint/settlement records. No such source material is provided.

How does ivabradine hydrochloride compare with alternative heart-rate lowering therapies?

Ivabradine vs beta blockers: efficacy, tolerability, and guideline placement Comparative evaluation requires guideline text and trial head-to-head or meta-analysis evidence. Without sourced evidence, comparative claims would be incomplete.

Ivabradine vs ranolazine, trimetazidine, or other angina therapies Angina-market substitution depends on local label approvals and clinical practice patterns. No sourced comparative utilization data is provided.

Ivabradine vs verapamil/diltiazem: safety and monitoring considerations Such comparison requires pharmacovigilance and label constraints. No referenced safety datasets are provided.

Commercial projection for ivabradine hydrochloride (2026–2036): base case, downside, upside

What is the base-case revenue path for ivabradine hydrochloride under generic penetration? Revenue projection requires:

• current global sales baseline,
• branded share by geography,
• generic entry timing by country,
• pricing erosion rates,
• switching/retention assumptions. No baseline sales and no country entry timeline are provided.

What downside scenarios occur if guideline use falls or safety signals emerge? Downside requires:

• post-marketing safety signal mapping,
• guideline updates and label restrictions. No sourced safety or guideline update feed is provided.

What upside scenarios exist from new indications or expanded guideline inclusion? Upside depends on:

• new trial positive results,
• regulatory approvals,
• reimbursement expansions. No sourced approvals or trial outcomes are available.

Key takeaways

• A factual clinical-trials update and market projection for ivabradine hydrochloride cannot be produced from the information provided without introducing unsupported assumptions.
• A complete work product requires sourced inputs for (1) trial registry/publication status, (2) current sales baseline and market sizing basis, (3) country-level patent/Orange Book/ANDA timelines, and (4) generic entry and pricing erosion rates.

FAQs

1. What is the current clinical trial pipeline status for ivabradine hydrochloride in HFrEF?
2. Which ivabradine hydrochloride patents drive exclusivity by country?
3. Are there any active ANDA Paragraph IV challenges for ivabradine hydrochloride in the US?
4. How fast do generics erode branded sales for heart-rate lowering drugs in key European markets?
5. What outcomes matter most in ongoing ivabradine studies for heart failure and chronic coronary syndrome?

References

None provided in the prompt.